Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies

NCT03858166 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT03858166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03858166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Secondary Prophylaxis Versus ANC< 1000/mm3 Administration of PEG-rhG-CSF in Patients Receiving Cytotoxic Chemotherapy for Gynecologic Malignancies
Lead sponsor
Shandong University
Phase
Phase 4
Overall status
Terminated
Start date
December 1, 2017
Completion date
December 31, 2020
Enrollment
68 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant chemotherapy, ovarian cancer, ovarian neoplasms